Pneumonia drug candidate wins fast-track designation from FDA

04/29/2013 | Pharmaceutical Business Review Online

The FDA granted fast-track status to Sanofi Pasteur and KaloBios Pharmaceuticals' KB001A, an experimental treatment for Pseudomonas aeruginosa-related pneumonia among people being treated with mechanical ventilation. The drug, a monoclonal antibody, is undergoing an early-stage study in the U.S.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC